Bayer Gets EU Panel Recommendation for Prostate Cancer Treatment

Bayer AG said Friday that the European Union’s Committee for Medicinal Products for Human Use has given a positive opinion on its darolutamide medicine as a new treatment for men with a particular type of prostate cancer.
The compound–jointly developed with ORION Corp. (271560.SE)–is recommended for men with non-metastatic castration-resistant prostate cancer who have a high risk of developing metastatic disease, the pharmaceutical firm said.
In most cases a recommendation leads to marketing approval. Bayer said that it expects a decision to be made in the coming months.

https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-Gets-EU-Medicines-Agency-Recommendation-for-Prostate-Cancer-Treatment-29920247/